GMAB – Genmab A/S
Float Short %
0.63
Margin Of Safety %
8
Put/Call OI Ratio
0.34
EPS Next Q Diff
-0.14
EPS Last/This Y
-0.02
EPS This/Next Y
0.07
Price
27.81
Target Price
31.61
Analyst Recom
1.78
Performance Q
20.49
Relative Volume
1.08
Beta
0.95
Ticker: GMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | GMAB | 23.3 | 0.36 | 0.08 | 3569 |
| 2025-08-18 | GMAB | 23.42 | 0.25 | 0.67 | 1453 |
| 2025-08-19 | GMAB | 23.82 | 0.27 | 0.01 | 1485 |
| 2025-08-20 | GMAB | 24.08 | 0.21 | 0.53 | 1814 |
| 2025-08-21 | GMAB | 24.42 | 0.22 | 0.08 | 1825 |
| 2025-08-22 | GMAB | 24.65 | 0.26 | 0.26 | 1720 |
| 2025-08-25 | GMAB | 24.3 | 0.25 | 0.75 | 1746 |
| 2025-08-26 | GMAB | 24.52 | 0.26 | 0.00 | 1768 |
| 2025-08-27 | GMAB | 24.78 | 0.26 | 0.14 | 1771 |
| 2025-08-28 | GMAB | 25.1 | 0.26 | 0.24 | 1772 |
| 2025-08-29 | GMAB | 24.86 | 0.26 | 1.67 | 1783 |
| 2025-09-02 | GMAB | 25.9 | 0.25 | 0.14 | 1780 |
| 2025-09-03 | GMAB | 27.07 | 0.25 | 0.33 | 1832 |
| 2025-09-04 | GMAB | 27.39 | 0.26 | 0.06 | 1980 |
| 2025-09-05 | GMAB | 27.55 | 0.27 | 0.53 | 1975 |
| 2025-09-08 | GMAB | 27.55 | 0.30 | 0.75 | 1957 |
| 2025-09-09 | GMAB | 27.84 | 0.30 | 0.21 | 1958 |
| 2025-09-10 | GMAB | 27.72 | 0.34 | 0.07 | 2014 |
| 2025-09-11 | GMAB | 28.63 | 0.34 | 0.06 | 2019 |
| 2025-09-12 | GMAB | 27.81 | 0.34 | 0.06 | 2003 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | GMAB | 23.31 | 53.2 | -689.1 | 1.75 |
| 2025-08-18 | GMAB | 23.42 | 53.2 | -707.3 | 1.75 |
| 2025-08-19 | GMAB | 23.82 | 53.2 | -698.9 | 1.75 |
| 2025-08-20 | GMAB | 24.07 | 53.2 | -693.7 | 1.75 |
| 2025-08-21 | GMAB | 24.42 | 53.2 | -696.7 | 1.73 |
| 2025-08-22 | GMAB | 24.65 | 53.2 | -705.8 | 1.73 |
| 2025-08-25 | GMAB | 24.30 | 53.2 | -715.4 | 1.73 |
| 2025-08-26 | GMAB | 24.54 | 53.2 | -710.6 | 1.73 |
| 2025-08-27 | GMAB | 24.78 | 53.2 | -702.5 | 1.73 |
| 2025-08-28 | GMAB | 25.11 | 53.2 | -699.4 | 1.73 |
| 2025-08-29 | GMAB | 24.86 | 53.2 | -719.6 | 1.73 |
| 2025-09-02 | GMAB | 25.90 | 53.2 | -683.1 | 1.73 |
| 2025-09-03 | GMAB | 27.09 | 53.2 | -500.6 | 1.73 |
| 2025-09-04 | GMAB | 27.39 | 53.2 | -537.5 | 1.73 |
| 2025-09-05 | GMAB | 27.54 | 53.2 | 174.4 | 1.73 |
| 2025-09-08 | GMAB | 27.54 | 58.3 | 168.4 | 1.68 |
| 2025-09-09 | GMAB | 27.85 | 58.3 | 200.6 | 1.68 |
| 2025-09-10 | GMAB | 27.72 | 58.3 | 168.0 | 1.68 |
| 2025-09-11 | GMAB | 28.61 | 58.3 | 219.0 | 1.68 |
| 2025-09-12 | GMAB | 27.81 | 58.3 | 107.1 | 1.68 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | GMAB | 0 | -0.45 | 0.58 |
| 2025-08-18 | GMAB | 0 | -0.41 | 0 |
| 2025-08-19 | GMAB | 0 | -0.41 | 0.58 |
| 2025-08-20 | GMAB | 0 | -0.41 | 0.58 |
| 2025-08-21 | GMAB | 0 | -0.41 | 0.58 |
| 2025-08-22 | GMAB | 0 | -0.41 | 0.58 |
| 2025-08-25 | GMAB | 0 | -0.15 | 0.58 |
| 2025-08-26 | GMAB | 0 | -0.15 | 0.58 |
| 2025-08-27 | GMAB | 0 | -0.15 | 0.56 |
| 2025-08-28 | GMAB | 0 | -0.15 | 0.56 |
| 2025-08-29 | GMAB | 0 | -0.15 | 0.56 |
| 2025-09-02 | GMAB | 0 | -0.18 | 0.56 |
| 2025-09-03 | GMAB | 0 | -0.18 | 0.56 |
| 2025-09-04 | GMAB | 0 | -0.18 | 0.56 |
| 2025-09-05 | GMAB | 0 | -0.18 | 0.56 |
| 2025-09-08 | GMAB | 0 | -0.21 | 0.56 |
| 2025-09-09 | GMAB | 0 | -0.21 | 0.56 |
| 2025-09-10 | GMAB | 0 | -0.21 | 0.56 |
| 2025-09-11 | GMAB | 0 | -0.21 | 0.63 |
| 2025-09-12 | GMAB | 0 | -0.21 | 0.63 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.54
Avg. EPS Est. Current Quarter
0.45
Avg. EPS Est. Next Quarter
0.4
Insider Transactions
Institutional Transactions
-0.21
Beta
0.95
Average Sales Estimate Current Quarter
6208
Average Sales Estimate Next Quarter
6510
Fair Value
30
Quality Score
100
Growth Score
99
Sentiment Score
89
Actual DrawDown %
43.3
Max Drawdown 5-Year %
-63.1
Target Price
31.61
P/E
13.89
Forward P/E
14.22
PEG
1.15
P/S
5.05
P/B
3.23
P/Free Cash Flow
17.02
EPS
2
Average EPS Est. Cur. Y
1.68
EPS Next Y. (Est.)
1.76
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
37.52
Relative Volume
1.08
Return on Equity vs Sector %
-1.7
Return on Equity vs Industry %
11.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.34
EBIT Estimation
107.1
Genmab A/SSector: Healthcare
Industry: Biotechnology
Employees: 2639
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading